Text Size

Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

This study has been completed.
Sponsor:
Information provided by:
Palatin Technologies
ClinicalTrials.gov Identifier:
NCT00686803
First received: May 27, 2008
Last updated: February 22, 2011
Last verified: February 2011
History of Changes
  Purpose

The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous (SC) PL-3994, relative to placebo in subjects with controlled hypertension. Including in this evaluation is the effect PL3994 has on blood pressure.


Condition Intervention Phase
Hypertension
 Drug: PL3994
Drug: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Single-Center, Single-Dose, Placebo-Controlled, Randomized, Double-Blind, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Palatin Technologies:

Primary Outcome Measures:
  • Safety (incidence of adverse events); Blood pressure and heart rate; natiuresis; diuresis; cGMP; pharmacokinetics [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 35
Study Start Date: May 2008
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PL3994 Dose A
PL3994 Dose A
 Drug: PL3994
Study drug
Experimental: PL3994 Dose B
PL3994 Dose B
 Drug: PL3994
Study drug
Experimental: PL3994 Dose C
PL3994 Dose C
 Drug: PL3994
Study drug
Experimental: PL3994 Dose D
PL3994 Dose D
 Drug: PL3994
Study drug
Experimental: PL3994 Dose E
PL3994 Dose E
 Drug: PL3994
Study drug
Placebo Comparator: Placebo
Placebo
 Drug: Placebo
Placebo

Detailed Description:

Uncontrolled hypertension, including both hypertensive urgency and hypertensive emergency, is commonly seen in emergency rooms and other urgent care settings. Current standards of care include intravenously administered drugs, which can be difficult to titrate and require ongoing monitoring. This study examines the effect of PL-3994 on patients with controlled hypertension who are receiving antihypertensive medications.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have had a diagnosis of essential hypertension for at least 1 year, per subject verbal history
  • Subject must be on a stable dose of at least one, but not more than 3 antihypertensive medications for at least 3 months, per subject verbal history.
  • Subject must have a systolic blood pressure at screening between 100 and 150 mmHg, and diastolic BP must not exceed 105 mmHg.

Exclusion Criteria:

  • Subject weight greater than 100 kg or less than 50 kg.
  • Any significant medical condition or abnormal safety laboratory results which, in the judgement of the Investigator would place the subject at significant risk.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00686803

Sponsors and Collaborators
Palatin Technologies
Investigators
Study Director: Steven Fischkoff, MD Palatin Technologies
Study Director: Robert Jordan Palatin Technologies
  More Information

No publications provided

Responsible Party: Robert Jordan/Director of Clinical Operations, Palatin Technologies
ClinicalTrials.gov Identifier: NCT00686803     History of Changes
Other Study ID Numbers: PL3994-003
Study First Received: May 27, 2008
Last Updated: February 22, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Palatin Technologies:
hypertension
controlled hypertension
hypertensives

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 18, 2013